In this episode, we will be talking about immunogenetics and systems biology of vaccine response and performance related to novel vaccines and adjuvants in adults and children with the Vaccine Research Group at the Mayo Clinic.  

The Vaccine Research Group is established at the Mayo Clinic in Rochester, Minnesota. The group works to improve the health of individuals throughout the world by addressing challenges posed by infectious diseases and bioterrorism through clinical, laboratory and epidemiologic vaccine research. Founded in 1989, the group is led by Gregory A. Poland, M.D. (founder), Richard B. Kennedy, Ph.D. and Inna G. Ovsyannikova, Ph.D.

This episode was recorded on October 25, 2024. Respiratory disease is an ever-changing topic in research and the status of infections across the US and around the world. Please see the Center for Disease Control and the US Department of Agriculture for the most up-to-date information on the status of infections and recommendations.

The information in this podcast is for educational purposes only and does not constitute medical advice or diagnosis.

The Nanovaccine Institute was founded at Iowa State University building upon core partnerships with the University of Iowa and the University of Nebraska Medical Center. Our purpose is to use nano-based technologies to tackle emergent diseases that have a devastating impact on human and animal health.

On today’s episode, we will be talking about the influenza virus in neonatal populations.

Dr. Jennifer Bermick is an Associate Professor of Pediatrics in Neonatology at the University of Iowa. She runs a basic science laboratory that focuses on understanding how the neonatal immune system develops under normal and inflammatory conditions. This includes the study of fetal and neonatal immune responses during chorioamnionitis and neonatal sepsis, with the goal of identifying therapies that can mitigate the morbidities and mortality associated with these conditions.

Dr. Kevin Legge is a Pathology Endowed Professor of Pulmonary Immunology Research, Vice Chair for Research in the Department of Pathology, Professor of Microbiology and Immunology, Director, Department of Pathology Research Flow Cytometry Facility, Director, Interdisciplinary Program in Immunology at the University of Iowa, and Associate Director at the Nanovaccine Institute.

This episode was recorded on September 23, 2024. Respiratory disease is an ever-changing topic in research and the status of infections across the US and around the world. Please see the Center for Disease Control and the US Department of Agriculture for the most up-to-date information on the status of infections and recommendations.

The information in this podcast is for educational purposes only and does not constitute medical advice or diagnosis.

The Nanovaccine Institute was founded at Iowa State University building upon core partnerships with the University of Iowa and the University of Nebraska Medical Center. Our purpose is to use nano-based technologies to tackle emergent diseases that have a devastating impact on human and animal health.

This episode discusses the emergence and evolution of avian H5N1.

Our episode guest is Kevin Legge, Pathology Endowed Professor of Pulmonary Immunology Research, Vice Chair for Research in the Department of Pathology, Professor of Microbiology and Immunology, Director, Department of Pathology Research Flow Cytometry Facility, Director, Interdisciplinary Program in Immunology at the University of Iowa, and Associate Director at the Nanovaccine Institute.

This episode was recorded on September 30, 2024. Respiratory disease is an ever-changing topic in research and the status of infections across the US and around the world. Please see the Center for Disease Control and the US Department of Agriculture for the most up-to-date information on the status of infections and recommendations.

The information in this podcast is for educational purposes only and does not constitute medical advice or diagnosis.

The Nanovaccine Institute was founded at Iowa State University building upon core partnerships with the University of Iowa and the University of Nebraska Medical Center. Our purpose is to use nano-based technologies to tackle emergent diseases that have a devastating impact on human and animal health.

This episode discusses the immune response to bovine respiratory infections in cattle, particularly the respiratory disease RSV.

Episode guests are: Jodi McGill, Interim Associate Dean of Research and Graduate Studies in the College of Veterinary Medicine and the John G. Salsbury Endowed Chair and Associate Professor in Veterinary Medicine at Iowa State University, and Randy Sacco, Lead Scientist and Research Microbiologist in Ruminant Diseases and Immunology Research Unit (RDIRU) at the National Animal Disease Center/USDA/ARS.

This episode was recorded on August 23, 2024. Respiratory disease is an ever-changing topic in research and the status of infections across the US. Please see the Center for Disease Control and the US Department of Agriculture for the most up-to-date information on the status of infections. 

The Nanovaccine Institute was founded at Iowa State University building upon core partnerships with the University of Iowa and the University of Nebraska Medical Center. Our purpose is to use nano-based technologies to tackle emergent diseases that have a devastating impact on human and animal health.

In this episode, Mike Roof sits down with Phil Gauger, Professor in the College of Veterinary Medicine at Iowa State University, to discuss respiratory disease in livestock. 

Conversation highlights include vaccine use in livestock, livestock-human zoonotic transfer opportunities, avian influenza in dairy cattle, livestock disease monitoring, and web-based tools at Iowa State to assist with disease monitoring and understanding data trends in disease spread among livestock.  

Links from this episode: 

ISU FLUture

https://vetmed.iastate.edu/vdl/resources/client-services/isu-fluture

PRRSView

https://prrsv.vdl.iastate.edu/

This episode was recorded on July 9, 2024. Respiratory disease is an ever-changing topic in research and the status of infections across the US. Please see the Center for Disease Control and the US Department of Agriculture for the most up-to-date information on the status of infections. 

The Nanovaccine Institute was founded at Iowa State University building upon core partnerships with the University of Iowa and the University of Nebraska Medical Center. Our purpose is to use nano-based technologies to tackle emergent diseases that have a devastating impact on human and animal health.

Podcast hosts Balaji Narasimhan, Kathleen Ross, and Mike Roof briefly discuss the work at the Nanovaccine Institute and the topics to be covered by the Nanovax Podcast. 

Balaji Narasimhan, Anson Marston Distinguished Professor and Vlasta Klima Balloun Faculty Chair, Department of Chemical and Biological Engineering, Iowa State University; Director, Nanovaccine Institute

Kathleen Ross, Core Facility Manager, Research and Development Engineer III, Nanovaccine Institute

Mike Roof, Chief Technology Officer, Vaccines, Diagnostics, and Immunotherapeutics bioscience platform, Office of the Vice President for Research, Iowa State University

The Nanovaccine Institute was founded at Iowa State University building upon core partnerships with the University of Iowa and the University of Nebraska Medical Center. Our purpose is to use nano-based technologies to tackle emergent diseases that have a devastating impact on human and animal health.

Welcome to the Nanovax Podcast, a Nanovaccine Institute-curated podcast sharing the latest research and advancements in nanomedicine for human and animal health. Focus areas address respiratory disease, antimicrobial resistance, neural disorders, cancer, aging, and animal respiratory disease. Season 1 will focus on respiratory disease and antimicrobial resistance.      

The Nanovaccine Institute was founded at Iowa State University building upon core partnerships with the University of Iowa and the University of Nebraska Medical Center. Our purpose is to use nano-based technologies to tackle emergent diseases that have a devastating impact on human and animal health.